Trametinib (Mekinist) is a reversible inhibitor of MEK1 and MEK2 kinases, playing a vital role in the treatment of BRAFV600E or V600K mutation-positive melanoma.
What are the precautions for Trametinib (Mekinist) administration?
Confirmation via Genetic Testing
Prior to the initiation of trametinib treatment, the presence of BRAFV600E or V600K mutations in tumor specimens must be confirmed using an FDA-approved detection method.
This is a critical prerequisite for ensuring treatment efficacy, which helps avoid ineffective therapy for ineligible patients.
Identification of Contraindicated Populations
Trametinib is not suitable for patients who have previously received BRAF inhibitor therapy.
Clinical studies have demonstrated that trametinib failed to exhibit clinical activity in patients with prior exposure to BRAF inhibitors.
Management of Women of Childbearing Potential
Trametinib may cause fetal harm, as it possesses embryotoxic and abortifacient effects.
Women of childbearing potential must use highly effective contraceptive measures during treatment and for 4 months after discontinuing the drug.
In case of suspected or confirmed pregnancy, healthcare providers should be contacted immediately.
Precautions During Trametinib (Mekinist) Treatment
Monitoring of Cardiac Function
Trametinib may induce cardiomyopathy, with an incidence rate of 7% reported in clinical trials.
Left ventricular ejection fraction (LVEF) assessment using echocardiography or multiple gated acquisition (MUGA) scan is required before treatment, 1 month after treatment initiation, and every 2–3 months thereafter.
If an asymptomatic absolute decrease in LVEF of ≥10% from baseline, along with a value below the lower limit of normal, is observed, treatment should be suspended for a maximum of 4 weeks.
Permanent treatment discontinuation is necessary in cases of symptomatic congestive heart failure, or an absolute decrease in LVEF of more than 20% from baseline with a value below the lower limit of normal.
Prevention of Ocular Complications
The incidence of retinal pigment epithelial detachment (RPED) is approximately 0.8%.
Patients experiencing any visual disturbances should undergo an ophthalmologic evaluation immediately.
Treatment should be suspended upon confirmation of RPED; permanent discontinuation is required if no improvement is observed within 3 weeks.
The incidence of retinal vein occlusion is 0.2%, and permanent treatment discontinuation is mandatory once diagnosed.
Monitoring of Pulmonary Symptoms
The incidence of interstitial lung disease or pneumonia is 1.8%.
Patients presenting with new or progressive pulmonary symptoms (e.g., cough, dyspnea, hypoxia, or infiltrates) should have treatment suspended, and clinical investigations should be initiated promptly.
